Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

November 17, 2024

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

News Conference News AHA 2021

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

Yael L. Maxwell

November 13, 2021

OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

News Conference News AHA 2020

OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

November 14, 2020

When PCI Decisions Ignore FFR Results, Patients Pay a Price

News Conference News AHA 2020

When PCI Decisions Ignore FFR Results, Patients Pay a Price

November 14, 2020

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

News Conference News AHA 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Yael L. Maxwell

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

News Conference News AHA 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

November 11, 2017

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

News Conference News AHA 2015

Varenicline Helps ACS Patients Quit Smoking, But Effect Wanes

November 12, 2015

News Conference News AHA 2012

Evidence Continues to Support Dabigatran Treatment in A-fib

November 06, 2012

News Conference News AHA 2012

TRILOGY ACS Substudy: No Relationship Between Platelet Reactivity, Outcomes

November 04, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.